1. Detection of activating and resistance mutations in single CTCs from EGFR-mutant non-small cell lung cancer patients treated by EGFR inhibitors;Oulhen;Clin. Exp. Metastasis,2018
2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries (vol 68, pg 394, 2018);Bray;Ca-Cancer J Clin,2020
3. Targeting EGFR(L858R/T790M) and EGFR(L858R/T790M/C797S) resistance mutations in NSCLC: current developments in medicinal chemistry;Lu;Med. Res. Rev.,2018
4. New treatment options for ALK plus advanced non-small-cell lung cancer: critical appraisal of ceritinib;Rothschild;Therapeut. Clin. Risk Manag.,2016
5. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations;Wang;Canc. Commun.,2019